Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

26.15 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 26.15
Bid (Size) 2.000 (1)
Ask (Size) 27.69 (1)
Prev. Close 26.15
Today's Range 26.15 - 26.15
52wk Range 16.75 - 50.98
Shares Outstanding 58,951,469
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Looking Into Agios Pharmaceuticals Return On Capital Employed
  
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-24.88%
-24.88%
1 Month
+20.95%
+20.95%
3 Month
+26.88%
+26.88%
6 Month
-11.24%
-11.24%
1 Year
-38.11%
-38.11%

More News

Read More
Agios Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022
Via Benzinga
Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Via Benzinga
U.S. Stock Futures Higher; All Eyes On Inflation Data
Via Benzinga
Delta Air Lines, Fastenal And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Analysts Have This to Say About Agios Pharmaceuticals
Via Benzinga
Agios Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
Analyst Ratings For Agios Pharmaceuticals
Via Benzinga
What 4 Analyst Ratings Have To Say About Agios Pharmaceuticals
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Via Benzinga
FDA Approves Agios' Mitapivat As First Disease-Modifying Therapy For Genetic Blood Disorder
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Via Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
Via InvestorPlace
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Via Talk Markets
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.